Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
-
CRITEO TO PRESENT AT THE CITI 2026 GLOBAL TMT CONFERENCE ON SEPTEMBER 8, 2026
-
Aldebaran Resources and Centauri Minerals Announce Final Approval of Centauri’s Listing on the TSX Venture Exchange
-
VERSABANK ANNOUNCES SIGNING OF REORGANIZATION AGREEMENT AND FILING AND MAILING OF MATERIALS FOR SPECIAL MEETING OF SHAREHOLDERS TO APPROVE PROPOSED REORGANIZATION
-
Informativ Named to the 2026 Inc. 5000 List of America's Fastest-Growing Private Companies
-
Amity Global Research Hub Launches in New York to Boost India-US Innovation
-
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
-
Nuveen Announces Closing of the Fourth Vintage of CPACE Lending Fund Series, Bringing Total Commitments to Over $3 Billion Since Inception in 2023
-
Radiology Partners to Acquire Everlight Radiology, Creating a Global Leader in Teleradiology
-
Big Brothers Big Sisters Twin Cities Announces Dr. Shana Ford as Next Chief Executive Officer
-
Joy Organics Expands Organic THC-Free CBD Gummy Line With New 50mg Strength and Sour Apple Flavor
-
Calumet to Attend Barclays Annual Energy-Power Conference
-
Addionics Introduces Battery Architecture for Low-Temperature Performance, Increasing Battery Operations and Charging Capabilities
-
Auxia Crossed 200B+ Decisions and Launches Agent Studio, the Operating System for the 10x Marketing Team
-
FutureProof Names Jonathan Mertz as Chief Business Officer
-
Infravision Announces the Appointment of Paul Gillespie as Director, Transmission Solutions
-
KuMining Broadens Access to Proof-of-Work Infrastructure with KAS Cloud Mining
-
Logitech Spot Just Made the Workplace Actually Responsive
-
Capital Square Expands National Accounts Team With Addition of Phillip Jensen
-
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
-
GoldInxs Strengthens Corporate Development and Investor Communications with Key Appointment and ICG Engagement
-
CLO Virtual Fashion Resolves Major US Patent Infringement Case, Secures Settlement Against Style3D
-
Pipedrive Report: the AI Paradox – Professionals Want AI as a Thinking Partner, Not an Autopilot
-
JOLT Launches Spark Intelligence in the U.S., Bringing Audience-Led Planning and Measurement to Digital Out-of-Home
-
Altesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year
-
Redwire Announces Strategic Investment in Next-Generation Phased Array Antenna Technology to Advance Global Warfighter Connectivity
-
MITER Brands’ PGT® WinGuard® Impact Windows are Top Rated by Consumer Reports®*
-
Ansaldo Energia Selects Kinaxis to Power the Future of Global Energy Infrastructure
-
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
-
Deep Fission Names ShawnTrell Scales as Its First Chief People Officer
-
United Adds 10 International Cities for 2027; Largest Expansion in Airline's History
-
UL Solutions Expands Capabilities in Italy to Create European Retail Center of Excellence Supporting Customers From Product Concept to Market
-
Hyundai Translead Strengthens Commercial Vehicle Network with Range Zero Emissions
-
Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations
-
Lumexa Imaging Announces Participation in Upcoming Investor Conferences
-
Lotus Tech Completed Acquisition of 100% Equity Interest of Lotus Advance Technologies, Integrating All Businesses and Operations Under One Lotus
-
Range Zero Emissions Announces Strategic Transformation; Becomes Largest Zero-Emission Group in US
-
Fareon Announces Oral Presentation of First-in-Class Biophysics Treatment Results in Patients with Cognitive Impairment from Long COVID at the 2026 ISLC-PAIS Annual Meeting
-
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
-
Troilus Selects Metso for Major Process Equipment as Project Advances Towards Construction
-
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
-
BrewDog Wins Big at the 2026 World Beer Awards with a Sweeping Show of Brewing Excellence
-
Trident Resources Announces the Commencement of an Airborne Magnetic and Radiometric Geophysical Survey over the Reindeer Gold Property
-
Canada-Japan Funding Fuels Xanadu and Mitsubishi Chemical Partnership on Quantum Semiconductor Research
-
Informativ Named to the 2026 Inc. 5000 List of America's Fastest-Growing Private Companies
-
Aveanna to Participate in the 2026 Jefferies Healthcare Services and Technology Conference
-
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
-
Immatics Announces $150 Million Underwritten Offering
-
New Found Gold Announces Graduation to the Toronto Stock Exchange
-
Statement regarding Intention to Launch Offer for Subscription
